Illumina (ILMN) GRAIL Merger Case
Illumina acquired Grail without securing regulatory approval, facing regulatory scrutiny and $0.5B in fines.
Since the acquisition news, $ILMN lost ~70% of shareholder value.
Investor suspects Illumina & its BoD of downplaying regulatory risk and not prioritizing shareholder interests in the GRAIL merger.
On August 18, 2021, Illumina (ILMN) announced that it acquired GRAIL, a healthcare company focused on life-saving early detection of multiple cancers but $ILMN will hold GRAIL as a separate company during the European Commission's ongoing regulatory review.
On 6 September 2022, the Commission prohibited the acquisition of GRAIL by Illumina over concerns that the merger would have stifled innovation and reduced choice in the emerging market for blood-based early cancer detection tests.
On July 12, 2023, EU regulators fined Illumina a record EUR 432 million for closing its acquisition of Grail without first securing regulatory approval.
On October 18, 2023, Activist-investor Carl Icahn sued the board of directors at $ILMN and accused them of breaching their fiduciary duties.
Investors have reasons to suspect that Illumina & its BoD downplayed the regulatory risk and did not act in the best shareholder interests by closing the GRAIL merger.